|1.||Priest, Birgit T: 11 articles (12/2010 - 08/2004)|
|2.||Kaczorowski, Gregory J: 10 articles (12/2010 - 08/2004)|
|3.||Martin, William J: 9 articles (12/2010 - 08/2004)|
|4.||Parsons, William H: 7 articles (12/2010 - 08/2004)|
|5.||Shimizu, Wataru: 6 articles (01/2012 - 02/2005)|
|6.||Lyons, Kathryn A: 6 articles (12/2010 - 04/2005)|
|7.||Brochu, Richard M: 5 articles (12/2010 - 08/2004)|
|8.||Waxman, Stephen G: 5 articles (01/2010 - 12/2006)|
|9.||Smith, McHardy M: 5 articles (09/2009 - 08/2004)|
|10.||Garcia, Maria L: 5 articles (09/2009 - 08/2004)|
01/01/2008 - "Sodium channel blockers can be effective in the treatment of pain. "
01/01/2004 - "Many types of pain appear to reflect neuronal hyperexcitability, and importantly, use-dependent sodium channel blockers are effective in the treatment of many types of chronic pain. "
01/01/2010 - "Our data suggest that ranalozine can attenuate hyperexcitability of DRG neurons over-expressing wild-type Nav1.7 channels, as occurs in acquired neuropathic and inflammatory pain, and thus merits further study as an alternative to existing non-selective sodium channel blockers."
01/01/2015 - "Thus while treatment of chronic pain remains an unmet clinical need, sodium channel blockers are considered as promising druggable targets. "
11/01/2014 - "Bioavailable pyrrolo-benzo-1,4-diazines as Na(v)1.7 sodium channel blockers for the treatment of pain."
|2.||Neuralgia (Stump Neuralgia)
01/01/2001 - "Sodium channel blockers have been reported to be effective in relieving neuropathic pain. "
01/01/2013 - "Sodium channel blockers currently used to treat neuropathic pain are poorly tolerated. "
11/01/2012 - "[Discovery of voltage-gated sodium-channel blockers for the treatment of neuropathic pain]."
01/01/2011 - "Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes."
06/01/2010 - "The continuous discoveries in the field of sodium channel blockers, highlighted by the increasing numbers of patent applications published in the last few years and by the numbers of compounds currently in clinical development, underline the importance of this target for the treatment of neuropathic pain. "
|3.||Hypertension (High Blood Pressure)
04/02/1997 - "Data from several large intervention trials in elderly patients with hypertension show that treatment of high blood pressure with potassium-sparing diuretics is clearly beneficial since cerebral and cardiac events are both significantly reduced. "
03/01/2013 - "MR antagonists are considered to be potassium-sparing diuretics that exert their effect by blocking MR in the kidney, and they are not the first choice for treating hypertension. "
10/01/2007 - "The most suitable diuretic treatment for hypertension is an association of low doses thiazide (12.5-50 mg/day) with potassium sparing diuretics. "
09/01/2006 - "Patients with sustained resistant hypertension had a significantly lower prescription rate of potassium-sparing diuretics than those with controlled hypertension. "
04/02/1997 - "The role of potassium-sparing diuretics in the treatment of hypertension is discussed. "
08/01/2010 - "Non-potassium-sparing diuretics (NPSDs) still remain the cornerstone of therapy for fluid management in heart failure despite the lack of large randomized trials evaluating their safety and optimal dosing regimens in both the acute and chronic setting. "
04/10/2008 - "Non-potassium-sparing diuretics may increase mortality and hospitalizations in heart failure patients. "
06/01/2006 - "Non-potassium-sparing diuretics are commonly used in heart failure (HF). "
08/20/2003 - "We sought to determine whether non-potassium-sparing diuretics (PSDs) in the absence of a PSD may result in progressive heart failure (HF). "
08/01/1995 - "Potassium-sparing diuretics are usually reserved for neonates with congestive heart failure and are always used in combination."
|5.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
07/01/2007 - "In vitro observations and studies in murine experimental autoimmune encephalomyelitis (EAE) have shown protective effects of sodium channel blockers on central nervous system axons and improved clinical status when treatment is continued throughout the period of observation. "
01/01/2014 - "This was assessed in the relapsing-progressive experimental autoimmune encephalomyelitis ABH mouse model of multiple sclerosis using conventional sodium channel blockers and a novel central nervous system-excluded sodium channel blocker (CFM6104) that was synthesized with properties that selectively target the inflammatory penumbra in experimental autoimmune encephalomyelitis lesions. "
12/01/2006 - "Two sodium channel blockers, phenytoin and flecainide, have been reported to protect axons in experimental autoimmune encephalomyelitis (EAE) for 30 days, but long-term protective effects have not been studied. "
06/15/2014 - "Sodium channel blockers, including phenytoin, carbamazepine, flecainide and lamotrigine, have been shown to protect axons from degeneration, attenuate immune cell infiltrates and slow the acquisition of neurological deficits in mice with experimental autoimmune encephalomyelitis (EAE), a model of MS. However, the sudden withdrawal of sodium channel blockers, phenytoin and carbamazepine, is associated with severe exacerbation of EAE characterized by massive inflammatory infiltrates and high mortality. "
|3.||Sodium Channels (Sodium Channel)
|9.||Epithelial Sodium Channel
|1.||Drug Therapy (Chemotherapy)
|2.||Fontan Procedure (Fontan Operation)
|3.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)